Matrix metalloproteinase-9: A magic drug target in neuropsychiatry?

被引:7
作者
Kaczmarek, Krzysztof T. [1 ,2 ]
Protokowicz, Karolina [3 ]
Kaczmarek, Leszek [3 ]
机构
[1] 2xN, London W1U 1PB, England
[2] Imperial Coll London, London SW7 2BW, England
[3] Nencki Inst, BRAINICITY, Pasteur 3, PL-02093 Warsaw, Poland
关键词
addiction; autism spectrum disorders; bipolar disorder; epilepsy; major depression; schizophrenia; LONG-TERM POTENTIATION; FRAGILE-X-SYNDROME; MATRIX METALLOPROTEINASES; SYNAPTIC PLASTICITY; SPECTRUM DISORDERS; MESSENGER-RNA; GELATINASE-B; MMP-9; LEVELS; MINOCYCLINE; BRAIN;
D O I
10.1111/jnc.15976
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuropsychiatric conditions represent a major medical and societal challenge. The etiology of these conditions is very complex and combines genetic and environmental factors. The latter, for example, excessive maternal or early postnatal inflammation, as well as various forms of psychotrauma, often act as triggers leading to mental illness after a prolonged latent period (sometimes years). Matrix metalloproteinase-9 (MMP-9) is an extracellularly and extrasynaptic operating protease that is markedly activated in response to the aforementioned environmental insults. MMP-9 has also been shown to play a pivotal role in the plasticity of excitatory synapses, which, in its aberrant form, has repeatedly been implicated in the etiology of mental illness. In this conceptual review, we evaluate the experimental and clinical evidence supporting the claim that MMP-9 is uniquely positioned to be considered a drug target for ameliorating the adverse effects of environmental insults on the development of a variety of neuropsychiatric conditions, such as schizophrenia, bipolar disorder, major depression, autism spectrum disorders, addiction, and epilepsy. We also identify specific challenges and bottlenecks hampering the translation of knowledge on MMP-9 into new clinical treatments for the conditions above and suggest ways to overcome these barriers.image Matrix metalloproteinase-9 (MMP-9) is an extracellularly and extrasynaptic operating protease that has been shown to play a functional role in a variety of physiological and pathological phenomena, including development, learning and memory, synaptic plasticity, and inflammation, as well as autism spectrum and mood disorders, schizophrenia, addiction and epileptogenesis. MMP-9 is markedly activated in response to various environmental insults, such as excessive maternal or early postnatal inflammation, as well as various forms of psychotrauma. Therefore, it can be proposed that MMP-9 is uniquely positioned to be considered a drug target for ameliorating the adverse effects of environmental insults on the development of a variety of neuropsychiatric conditions.image
引用
收藏
页码:1842 / 1853
页数:12
相关论文
共 131 条
  • [1] Amniotic Fluid MMP-9 and Neurotrophins in Autism Spectrum Disorders: An Exploratory Study
    Abdallah, Morsi W.
    Pearce, Brad D.
    Larsen, Nanna
    Greaves-Lord, Kirstin
    Norgaard-Pedersen, Bent
    Hougaard, David M.
    Mortensen, Erik L.
    Grove, Jakob
    [J]. AUTISM RESEARCH, 2012, 5 (06) : 428 - 433
  • [2] Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression
    Alaiyed, Seham
    McCann, Mondona
    Mahajan, Gouri
    Rajkowska, Grazyna
    Stocicmeier, Craig A.
    Kellar, Kenneth J.
    Wu, Jian Young
    Conant, Katherine
    [J]. JOURNAL OF NEUROSCIENCE, 2020, 40 (22) : 4418 - 4431
  • [3] A Role for Matrix Metalloproteases in Antidepressant Efficacy
    Alaiyed, Seham
    Conant, Katherine
    [J]. FRONTIERS IN MOLECULAR NEUROSCIENCE, 2019, 12
  • [4] Venlafaxine stimulates PNN proteolysis and MMP-9-dependent enhancement of gamma power; relevance to antidepressant efficacy
    Alaiyed, Seham
    Bozzelli, P. Lorenzo
    Caccavano, Adam
    Wu, Jian Young
    Conant, Katherine
    [J]. JOURNAL OF NEUROCHEMISTRY, 2019, 148 (06) : 810 - 821
  • [5] Quantifying the global burden of mental disorders and their economic value
    Arias, Daniel
    Saxena, Shekhar
    Verguet, Stephane
    [J]. ECLINICALMEDICINE, 2022, 54
  • [6] Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients
    Arout, Caroline A.
    Waters, Andrew J.
    MacLean, R. Ross
    Compton, Peggy
    Sofuoglu, Mehmet
    [J]. PSYCHOPHARMACOLOGY, 2019, 236 (10) : 2857 - 2866
  • [7] Synapse formation: from cellular and molecular mechanisms to neurodevelopmental and neurodegenerative disorders
    Batool, Shadab
    Raza, Hussain
    Zaidi, Jawwad
    Riaz, Saba
    Hasan, Sean
    Syed, Naweed, I
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 2019, 121 (04) : 1381 - 1397
  • [8] MMPs in learning and memory and neuropsychiatric disorders
    Beroun, Anna
    Mitra, Shiladitya
    Michaluk, Piotr
    Pijet, Barbara
    Stefaniuk, Marzena
    Kaczmarek, Leszek
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (16) : 3207 - 3228
  • [9] Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors
    Bertran, Alexandra
    Khomiak, Danylo
    Konopka, Anna
    Rejmak, Emilia
    Bulska, Ewa
    Seco, Jesus
    Kaczmarek, Leszek
    Tarrago, Teresa
    Prades, Roger
    [J]. BIOORGANIC CHEMISTRY, 2020, 94
  • [10] Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior
    Bijata, Monika
    Baczynska, Ewa
    Mueller, Franziska E.
    Bijata, Krystian
    Masternak, Julia
    Krzystyniak, Adam
    Szewczyk, Bernadeta
    Siwiec, Marcin
    Antoniuk, Svitlana
    Roszkowska, Matylda
    Figiel, Izabela
    Magnowska, Marta
    Olszynski, Krzysztof H.
    Wardak, Agnieszka D.
    Hogendorf, Adam
    Ruszczycki, Blazej
    Gorinski, Nataliya
    Labus, Josephine
    Stepien, Tomasz
    Tarka, Sylwia
    Bojarski, Andrzej J.
    Tokarski, Krzysztof
    Filipkowski, Robert K.
    Ponimaskin, Evgeni
    Wlodarczyk, Jakub
    [J]. CELL REPORTS, 2022, 38 (11):